Phase 1 Pancreatic Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 or older (children are not included in this trial because safety information for that age group is not yet available).
• People whose general health and ability to carry out daily activities meets a minimum functional level, as assessed by their doctor (confirm with trial site).
• People, or their legally authorised representative, who are able to understand the study and are willing to provide written consent to participate.
• People who have been diagnosed with one of three specific cancer types through tissue or cell testing: pancreatic ductal adenocarcinoma, hepatocellular carcinoma (HCC), or invasive lobular carcinoma (a type of breast cancer).
• People who either have a suspected spread of cancer to other parts of the body based on scans or clinical assessment, or who have a confirmed spread but where doctors suspect the cancer may be more widespread than currently known, which could change the treatment plan.
• People who have at least one tumour or lesion that is large enough to be clearly measured on standard medical imaging (such as CT, MRI, or FDG PET-CT scans), meeting specific size thresholds depending on the type of scan used (confirm with trial site).
• People who are willing and able to undergo a biopsy if required as part of their standard care, to confirm findings from the PYLARIFY PET-CT scan, or who are planned for clinical follow-up instead.
• People who are either about to begin cancer treatment for the first time, or who are currently receiving treatment but are not responding as well as hoped, and whose doctor is planning a biopsy of a suspected area of spread — with the PYLARIFY PET-CT scan to be done at least one day before that biopsy.
• People with a life expectancy of at least three months, as determined by the treating doctor or investigator.

Who may not be able to join:

• People who are pregnant or breastfeeding, as there is currently no safety information available about the effects of the scan agent (piflufolastat F18) on unborn babies, infants, or milk production.
• People who have had an allergic reaction to PSMA PET scan agents in the past.
• People whose mental health conditions or personal circumstances may make it difficult to follow the study requirements.
• People who are unable to lie flat or tolerate a PET-CT scan.
• People who have received chemotherapy, immunotherapy, or radiotherapy within the four weeks before receiving the PYLARIFY scan agent.
• People who are receiving certain hormone-related therapies that target the androgen pathway (such as androgen deprivation therapy or androgen receptor blockers), as these may affect how the scan agent behaves — the impact on scan accuracy has not yet been established (confirm with trial site).
• People with any medical condition or circumstance that the investigator believes could affect their safety or the reliability of the study results.
• People diagnosed with other types of pancreatic, liver, or breast cancers that are not the three specific types listed in the inclusion criteria.

Important: Always verify eligibility with the trial site directly before applying.